Mandate

Vinge advises Active Biotech in its new issue

April 06, 2009

Vinge has advised Active Biotech in its new issue of shares subject to pre-emption rights for the existing shareholders. Under the new issue, which is underwritten in its entirety by the principal shareholders MGA Holding and Nordstjernan, Active Biotech receives approximately SEK 256 million.

Vinge’s team was led by Erik Sjöman who was assisted by, among others, associates Christian Lindhé, Karolina Tjärnberg Jansson and Maria Doeser (tax law advice).

Related

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026

Vinge advises PPI Public Property Invest AB (publ) in connection with cross-border merger and listing on Nasdaq Stockholm and Euronext Oslo Børs

Vinge has advised PPI Public Property Invest AB (publ) (“PPI”) in connection with its listing on Nasdaq Stockholm and secondary listing on Euronext Oslo Børs. The listing was carried out through a cross-border merger whereby PPI absorbed Public Property Invest ASA, whose shares were previously listed on Euronext Oslo Børs.
May 20, 2026

Vinge represents Triton in connection with the sale of Aleris

Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026